Guideline for the treatment of myelodysplastic syndromes (MDS) in South Africa

Simple item page
dc.contributor.authorLouw, V
dc.contributor.authorBassa, F
dc.contributor.authorChan, S
dc.contributor.authorDreosti, L
dc.contributor.authorToit, M
dc.contributor.authorFerreira, M
dc.contributor.authorGartrell, K
dc.contributor.authorGunther, K
dc.contributor.authorJogessar, V
dc.contributor.authorLittleton, N
dc.contributor.authorMahlangu, J
dc.contributor.authorMcDonald, A
dc.contributor.authorPatel, M
dc.contributor.authorPool, R
dc.contributor.authorRuff, P
dc.contributor.authorSchmidt, A
dc.contributor.authorSissolak, G
dc.contributor.authorSwart, A
dc.contributor.authorVerburgh, E
dc.contributor.authorWebb, M
dc.date.accessioned2021-10-08T07:17:58Z
dc.date.available2021-10-08T07:17:58Z
dc.date.issued2011
dc.description.abstractABSTRACT INTRODUCTION: Myelodysplastic syndromes (MDS) encompass a heterogeneous group of clonal haematopoietic disorders characterised by chronic and progressive cytopenias resulting from ineffective haematopoiesis. Treatment is complicated by differences in disease mechanisms in different subgroups, variable clinical phenotypes and risk of progression to acute myeloid leukaemia. RATIONALE: Changes in disease classification, prognostic scoring systems, the availability of novel treatment options and the absence of South African guidelines for the diagnosis and management of these complex disorders underpinned the need for the development of these recommendations. METHODS: These recommendations are based on the opinion of a number of experts in the field from the laboratory as well as clinical settings and came from both the private and institutional academic environments. The most recent literature as well as available guidelines from other countries were discussed and debated at a number of different meetings held over a 2-year period. RESULTS: A comprehensive set of recommendations was developed focusing on risk stratification, supportive management and specific treatment. Novel agents and their indications are discussed and recommendations are made based on best available evidence and taking into account the availability of treatments in South Africa. CONCLUSION: Correct diagnosis, risk stratification and appropriate therapeutic choices are the cornerstones of success in the management of patients with MDS.
dc.identifier.apacitationLouw, V., Bassa, F., Chan, S., Dreosti, L., Toit, M., Ferreira, M., ... Webb, M. (2011). Guideline for the treatment of myelodysplastic syndromes (MDS) in South Africa. <i>South African Medical Journal</i>, 101(12), 900 - 906. http://hdl.handle.net/11427/34873en_ZA
dc.identifier.chicagocitationLouw, V, F Bassa, S Chan, L Dreosti, M Toit, M Ferreira, K Gartrell, et al "Guideline for the treatment of myelodysplastic syndromes (MDS) in South Africa." <i>South African Medical Journal</i> 101, 12. (2011): 900 - 906. http://hdl.handle.net/11427/34873en_ZA
dc.identifier.citationLouw, V., Bassa, F., Chan, S., Dreosti, L., Toit, M., Ferreira, M., Gartrell, K. & Gunther, K. et al. 2011. Guideline for the treatment of myelodysplastic syndromes (MDS) in South Africa. <i>South African Medical Journal.</i> 101(12):900 - 906. http://hdl.handle.net/11427/34873en_ZA
dc.identifier.issn0038-2469
dc.identifier.ris TY - Journal Article AU - Louw, V AU - Bassa, F AU - Chan, S AU - Dreosti, L AU - Toit, M AU - Ferreira, M AU - Gartrell, K AU - Gunther, K AU - Jogessar, V AU - Littleton, N AU - Mahlangu, J AU - McDonald, A AU - Patel, M AU - Pool, R AU - Ruff, P AU - Schmidt, A AU - Sissolak, G AU - Swart, A AU - Verburgh, E AU - Webb, M AB - ABSTRACT INTRODUCTION: Myelodysplastic syndromes (MDS) encompass a heterogeneous group of clonal haematopoietic disorders characterised by chronic and progressive cytopenias resulting from ineffective haematopoiesis. Treatment is complicated by differences in disease mechanisms in different subgroups, variable clinical phenotypes and risk of progression to acute myeloid leukaemia. RATIONALE: Changes in disease classification, prognostic scoring systems, the availability of novel treatment options and the absence of South African guidelines for the diagnosis and management of these complex disorders underpinned the need for the development of these recommendations. METHODS: These recommendations are based on the opinion of a number of experts in the field from the laboratory as well as clinical settings and came from both the private and institutional academic environments. The most recent literature as well as available guidelines from other countries were discussed and debated at a number of different meetings held over a 2-year period. RESULTS: A comprehensive set of recommendations was developed focusing on risk stratification, supportive management and specific treatment. Novel agents and their indications are discussed and recommendations are made based on best available evidence and taking into account the availability of treatments in South Africa. CONCLUSION: Correct diagnosis, risk stratification and appropriate therapeutic choices are the cornerstones of success in the management of patients with MDS. DA - 2011 DB - OpenUCT DP - University of Cape Town IS - 12 J1 - South African Medical Journal LK - https://open.uct.ac.za PY - 2011 SM - 0038-2469 T1 - Guideline for the treatment of myelodysplastic syndromes (MDS) in South Africa TI - Guideline for the treatment of myelodysplastic syndromes (MDS) in South Africa UR - http://hdl.handle.net/11427/34873 ER - en_ZA
dc.identifier.urihttp://hdl.handle.net/11427/34873
dc.identifier.vancouvercitationLouw V, Bassa F, Chan S, Dreosti L, Toit M, Ferreira M, et al. Guideline for the treatment of myelodysplastic syndromes (MDS) in South Africa. South African Medical Journal. 2011;101(12):900 - 906. http://hdl.handle.net/11427/34873.en_ZA
dc.language.isoeng
dc.publisher.departmentDivision of Haematology
dc.publisher.facultyFaculty of Health Sciences
dc.sourceSouth African Medical Journal
dc.source.journalissue12
dc.source.journalvolume101
dc.source.pagination900 - 906
dc.source.urihttps://dx.doi.org/10.7196/sajs.718
dc.subject.otherTreatment
dc.subject.otherMyelodysplastic syndromes (MDS)
dc.subject.otherMyelodysplastic syndromes -- South Africa
dc.subject.otherArticle
dc.titleGuideline for the treatment of myelodysplastic syndromes (MDS) in South Africa
dc.typeJournal Article
uct.type.publicationResearch
uct.type.resourceJournal Article
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
LouwV_Guideline_for_t_2011.pdf
Size:
370.42 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Journal Articles